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ess: aagusti@hsd.es (A.Summary Chronic obstructive pulmonary disease (COPD) is a multicomponent
disease. These components affect both the lungs and organs outside the lungs (the so-
called systemic effects of COPD) and can be of either a structural (including airway
remodelling, emphysema, skeletal muscle wasting) or functional nature (inflamma-
tion, apoptosis, senescence). Further, these components are interdependent in a
closely linked ‘vicious cycle’. Accordingly, optimal therapies should therefore aim to
address more than one of these components to break such a cycle. This needs to be
considered not only in the development of future treatments but also in the current
clinical management of patients with COPD. In this paper, evidence that supports the
concept that COPD is a multicomponent disease is presented. The effects of currently
available therapeutic options, including long-acting anticholinergics and long-acting
beta2-agonist/inhaled corticosteroid combination therapies, upon each of these
components is reviewed. In addition, potential new avenues for drug development and
improved patient care are highlighted. By developing a better understanding of how
different therapies impact upon the ‘vicious cycle’ of COPD, treatment regimens can
be optimised to provide the greatest benefits to patients.
& 2004 Elsevier Ltd. All rights reserved.The size of the problem
Chronic obstructive pulmonary disease (COPD) is a
major health problem. The World Health Organiza-
tion (WHO) has predicted that COPD will become
the fifth largest disease burden and the third
greatest cause of death by 2020.1 Because COPD
is not usually detected until patients seek medical
attention for dyspnoea or an exacerbation of theElsevier Ltd. All rights reserv
75 228.
G.N. Agusti).disease,2 COPD is an under-diagnosed disease and,
thus, available prevalence and mortality data are
likely to greatly underestimate the total burden to
patients and healthcare providers. There is, there-
fore, a need to improve our diagnostic and
therapeutic options for such a devastating disease.COPD is a multicomponent disease
Our traditional understanding of COPD has focused
on the presence of chronic airflow obstruction and,ed.
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relieve this. More recently, we have realised that
this airflow limitation is associated with an abnor-
mal inflammatory response, and that the latter
appears to be responsible for specific effects on
mucociliary function, some structural changes in
the airways and lung parenchyma, and, as is likely,
some of the effects outside the lung (the systemic
effects of COPD). In this context, COPD can be
considered a multicomponent disease, comprising
structural and functional changes, inside and out-
side the lungs (Fig. 1). These multiple components
are closely interdependent in what can be con-
sidered ‘the vicious cycle of COPD 3,4 (Fig. 2).Elements of the Disease—the vicious
cycle of COPD
Mucociliary dysfunction
The exposure to initiating factors (mostly cigarette

















Figure 2 The COPDglands (hypertrophy) and an increase in the number
of the mucus-secreting goblet cells.5 In addition,
the ciliated epithelium becomes damaged, result-
ing in decreased mucociliary transport. The combi-
nation of mucus hypersecretion and decreased
mucociliary transport, leads to an accumulation of
mucus within the airways, which increases the
likelihood of recurrent respiratory infections. Bac-
terially induced damage to the epithelium leads to
further cilial loss, and may further impair mucus
clearance and the epithelial defence function
(reduced secretion of defensins and other anti-
microbial peptides).6 In addition, bacterial coloni-
sation of accumulated mucus can stimulate the
inflammatory response, which, as discussed below,
represents one of the core components of the
vicious cycle of COPD.
Mucociliary dysfunction is not an innocent by-
stander and has direct clinical consequences. The
Copenhagen City Heart Study Group, a large
population study, demonstrated that chronic mucus
secretion was associated with accelerated decline
of lung function and increased hospitalizations due
to COPD, suggesting that mucociliary dysfunction
may contribute to the decline in forced expiratory
volume (FEV1) often seen in these patients.
7The inflammatory component
Exposure to initiating noxious substances (mostly
tobacco smoke) stimulates a ‘‘physiological’’ in-
flammatory response, whereby the lungs are
infiltrated by neutrophils, macrophages and lym-
phocytes.8–10 Whether the type or intensity of this
inflammatory reaction is different in smokers with
and without COPD is a matter of intense research.
In any case, in patients with COPD these inflam-
matory cells can release pro-inflammatory and












A.G.N. Agusti672interleukin-8 (IL-8), leukotriene B-4 (LTB4), matrix
metalloproteinases (MMPs) and tumour necrosis
factor a (TNFa), which further damage airway tissue
and sustain airway inflammation by attracting more
cells to the area.11,12 This cycle of chronic inflam-
mation leads to permanent structural changes in the
airways, including fibrosis, alveolar destruction and
epithelial hyperplasia, all of which contribute to
chronic airflow obstruction. Finally, it is worth
noting that the inflammatory cascade in the airways
can also induce mucous gland hypertrophy and
goblet cell metaplasia, which further aggravates
the mucociliary dysfunction and mucus accumula-
tion components of COPD discussed above.13–15The systemic component
The systemic component of COPD is an important
part of the vicious cycle, and should always be
considered in the clinical management of patients
with COPD. It is thought that extrapulmonary
inflammation is pivotal in the pathogenesis of the
systemic component of COPD. Not only can the
elevated levels of inflammatory mediators such as
IL-8 and TNF-a in the lungs escape to the peripheral
circulation, but they are also likely to be involved in
priming of circulating inflammatory cells. Other
potential contributors to the systemic effects of
COPD include, among others, tissue hypoxia, oxida-
tive stress, sedentarism and other metabolic ab-
normalities. The systemic effects more commonly
associated with COPD include skeletal muscle
dysfunction, nutritional abnormalities and weight
loss, cardiovascular and nervous system abnormal-
ities, and osteoskeletal effects such as osteoporo-
sis.16,17 In particular, skeletal muscle dysfunction
significantly limits the exercise capacity of patients
with COPD. It is thought that muscle dysfunction in
patients with COPD is due to both a reduction in
muscle mass, and malfunction of the remaining
muscle resulting, in part, from the abnormalities of
pulmonary gas exchange that characterise COPD.17
The reduction in muscle mass and severe weight loss
of patients with COPD may also be related to the
increased levels of circulating TNF-a, which can lead
to skeletal muscle apoptosis.18 The extent to which
systemic effects contribute to the overall pathology
of COPD varies from patient to patient, and will
depend on other factors such as genetic predisposi-
tion, confounding conditions such as heart disease
and diabetes, as well as whether or not the patient
continues to smoke.
In summary, COPD has to be considered a multi-
component disease, with both pulmonary and
extrapulmonary consequences. Accordingly, anoptimal therapy for COPD should treat the multi-
component nature of the disease. The goals of
effective COPD management (as defined by the
Global Initiative for Chronic Obstructive Lung
Disease [GOLD] guidelines) include a reduction in
symptoms, complications and exacerbations, im-
proved exercise tolerance, improved health status
and reduced mortality.2 Ideally, any form of
treatment should also have an impact on disease
progression. Some current and future therapies
have the potential to achieve these goals.Breaking the COPD vicious
cycle—current therapies
Several currently available agents act on different
aspects of the disease, as depicted in Fig. 3.
Bronchodilators
Bronchodilator therapy plays an important role in
the treatment of COPD. Despite the fact that
airflow limitation is generally poorly reversible in
COPD patients due to fixed, structural abnormal-
ities within the lungs, there is often a reversible
component. In a study of 660 patients meeting
European Respiratory Society (ERS) diagnostic
criteria for irreversible COPD, 38.2% of patients
were found to change their responder status, as
measured using spirometric parameters, between
visits. When American Thoracic Society (ATS)
criteria for bronchodilator responsiveness were
used, 52.1% of patients changed status between
visits.19 Further, it is possible that the measure of
the forced expiratory volume in 1 s (FEV1) may not
be the optimal method to assess the response to
bronchodilator therapy in these patients. Other
measures, such as changes in lung volume (inspira-
tory capacity) may prove more sensitive to the
effects of these drugs (the so-called ‘pharmacolo-
gical volume reduction’). Commonly used bronch-




A number of anticholinergic drugs are currently
used for the treatment of COPD, including ipra-
tropium bromide, oxitropium and tiotropium. Ipra-
tropium bromide and oxitropium have a relatively
short duration of action (4–6 h) and therefore
require multiple daily administration.22,23 In con-
trast, the newer anticholinergic agent tiotropium,
has a prolonged duration of action of more than
24 h and can therefore be taken once daily.
ARTICLE IN PRESS
Figure 3 Breaking the COPD vicious cycle.
COPD, a multicomponent disease: implications for management 673Tiotropium has additional advantages over older
anticholinergics, in that it has a 10-times greater
affinity for the M1 and M3 muscarinic receptor
subtypes, compared with ipratropium. The human
lung has five subtypes of muscarinic receptors, of
which M1 and M3 are the most important in
mediation of bronchoconstriction. Two 1-year stu-
dies have shown that in patients with COPD,
tiotropium (18mcg once daily) is associated with
improvements in bronchodilation, dyspnoea, and
quality of life, as well as reduced exacerbations
(20% vs. placebo, P ¼ 0:045; and 24% vs. ipratro-
pium, P ¼ 0:006) compared with placebo and
ipratropium.24,25 Dry mouth may limit compliance
in some patients. 26,27 A 6-month study comparing
tiotropium with the long-acting beta2-agonist sal-
meterol, and placebo, found that tiotropium and
salmeterol were both significantly superior to
placebo in the treatment of COPD, in terms of
trough FEV1, peak FEV1, and average FEV1 (0–12 h),
with tiotropium statistically significantly superior
to salmeterol in terms of mean FEV1.
28
Stimulation of the nerves via muscarinic recep-
tors causes bronchoconstriction and mucus secre-
tion.22 Therefore anticholinergic bronchodilators,
which block the muscarinic receptors, may also
reduce mucus secretion, thus targeting two im-
portant elements of the vicious cycle of COPD
(Fig. 3). However, this latter effect is difficult to
demonstrate in vivo. Indeed, a recent, randomized,
double-blind, controlled trial could not find evi-
dence of retardation of mucus clearance from the
lungs in COPD patients treated with tiotropium.29Beta2-agonists
Beta2-agonists mediate their bronchodilatory ef-
fects by stimulating the beta2-adrenoreceptors
found throughout bronchial smooth muscle. Stimu-
lation of these receptors results in relaxation of the
airway smooth muscle, thus relieving airflow
limitation.26,30
Short-acting beta2-agonists have been used in the
treatment of COPD for many years, and provide
effective short-term relief from bronchoconstric-
tion. Although this is useful on an as-required basis
and provides immediate relief, bronchoconstriction
is not the only cause of airflow limitation.
Furthermore, these agents are often considered
inconvenient to use for regular maintenance
therapy, as their short duration of action means
that they have to be taken at multiple intervals
throughout the day, which may influence patient
compliance.
Long-acting beta2-agonists (LABAs), such as sal-
meterol and formoterol, are available for the
treatment of COPD, and are more convenient than
short-acting beta2-agonists for regular mainte-
nance therapy, due to their extended period of
action and twice-daily dosing. The longer duration
of action of salmeterol may be due to an ability to
interact with the beta2-receptor through a second
binding site, whereas the prolonged action of
formoterol may be related to its partitioning within
the cell membrane.27
Short term (12-week), randomised, placebo-
controlled trials in patients with COPD have shown
that treatment with salmeterol (bid) results in
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12 h,31 and greater time-to-first COPD exacerba-
tion, when compared with either placebo or
ipratropium bromide.32 This treatment difference
reflects the longer duration of action of salmeterol,
as peak responses were generally similar to those
seen with ipratropium bromide. The effects of
salmeterol have been shown to be maintained in a
long-term (12-month) trial where salmeterol in-
duced a 20% reduction in exacerbation rate
compared with placebo.33 Beneficial effects on
lung function have similarly been reported with
formoterol where it has been shown to provide
significantly greater improvements in lung function
and reduced symptoms compared with placebo 34
and ipratropium bromide.35 One long-term (12-
month) study reported that treatment with for-
moterol was more effective and better tolerated
than slow-release theophylline.36 However, another
study found no significant difference in exacerba-
tion rate with formoterol compared with placebo,
over a 1-year period.37
In addition to their bronchodilatory effects,
salmeterol and formoterol have both been shown
to improve mucociliary dysfunction by increasing
mucus clearance. A study in healthy subjects
revealed that salmeterol led to greater improve-
ments in mucociliary transport compared with
placebo,38 and formoterol was shown to provide
increased mucociliary clearance compared with
placebo in patients with bronchitis.39 The muco-
ciliary effects of LABAs may be due to an increase in
ciliary beat frequency, as demonstrated in studies
on the effects of salmeterol in human bronchial
epithelial cells.40 Salmeterol has also been shown
to decrease bacterially induced tissue damage in
vitro, which is thought to account for the reduced
incidence of respiratory tract infection associated
with its use.32,41 There is also evidence of anti-
inflammatory effects with LABAs. Studies have
shown that LABAs have multiple effects on neu-
trophil activity, by acting on beta2-adrenoreceptors
found on neutrophils. Salmeterol has been shown to
inhibit neutrophil adhesion to human airway
epithelial cells,42 and both salmeterol and formo-
terol have been shown to inhibit neutrophil adhe-
sion to the vascular endothelium in experimental
animal models.43,44
In addition, a study in healthy subjects found
that therapeutic doses of inhaled salmeterol
resulted in an increase in respiratory muscle
activity.45 As such, salmeterol may potentially have
an effect on the systemic component of COPD by
improving skeletal muscle function, although
further research to confirm this is required.
Because of their many effects on respiratoryfunction, LABAs are capable of addressing multiple
components of the vicious cycle of COPD.Methyxanthines
For many years, theophylline, a non-selective
phosphodiesterase (PDE) inhibitor, has been the
cornerstone of COPD therapy—it was the only
therapy known to induce bronchodilation and
improve FEV1 in patients with COPD.
46,47 However,
its narrow therapeutic range, frequency of unde-
sired adverse events and potential to interact with
other drugs limits its current use in clinical
practice.48 Selective PDE inhibitors may overcome
these limitations and prove to be more effective
treatments for COPD, as discussed below.
On the other hand, recent data has shown that
theophylline may have some anti-inflammatory
effects on top of its bronchodilator effects. Hence,
low-dose theophylline treatment has been shown to
reduce neutrophil numbers in induced sputum by
22%, and to inhibit neutrophil chemotaxis by 28% in
patients with COPD.49 The exact mechanism by
which theophylline may exert this anti-inflamma-
tory action is not well understood, but it seems to
be unrelated to PDE inhibition because at low doses
the degree of PDE inhibition is small. Other
plausible molecular mechanisms may include ade-
nosine receptor antagonism, IL-10 release, effects
on transcription control (through its effects upon
histone acetylation) and apoptosis.50 The effects of
theophylline on histone aceytlation may be poten-
tially useful to enhance the anti-inflammatory
effects of steroids in COPD.51Inhaled steroids
As airway inflammation represents one of the
critical components of the vicious cycle of COPD,
inhaled corticosteroids (ICSs), such as fluticasone
propionate and budesonide, which have anti-
inflammatory properties, have the potential to
play an important part in the treatment of COPD.
ICSs have been shown to decrease the number of
neutrophils present in the lung, and to prevent the
release of pro-inflammatory mediators such as IL-8,
which would usually amplify the inflammatory state
by recruiting further inflammatory cells to the
area.52,53 A recent study in patients with COPD
revealed that fluticasone propionate inhibited
macrophage-derived cytokine release (IL-8 and
TNF-a) compared with placebo.54 Fluticasone pro-
pionate has also been shown to decrease the ratio
of CD8:CD4 cells in the epithelium and the numbers
of subepithelial mast cells in bronchial biopsies of
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placebo.55
In terms of effect on COPD, significant improve-
ments in pre-dose FEV1 have been observed with
fluticasone propionate vs. placebo in COPD patients
over 1 year.33 In addition, short-term studies in
COPD patients with budesonide have shown im-
provements in mean FEV1, and a reduced need for
rescue medication, compared with placebo.56 A
number of randomised, placebo-controlled trials
have been performed to assess the long-term effect
of ICS therapy in COPD.57–60 Although these studies
did not reveal any significant effect of ICSs over
placebo in terms of the rate of lung function
decline over 3 years, some important benefits were
seen. In the EUropean Respiratory Society study on
Chronic Obstructive Pulmonary disease (EURO-
SCOP) trial in patients with mild COPD who
continued smoking, a significant benefit with
budesonide over placebo in FEV1 was seen initially,
although this effect disappeared with long-term
treatment.60 In a further study in COPD patients,
inhaled triamcinolone did not slow the rate of
decline in lung function compared with placebo,
but improvements in airway reactivity and respira-
tory symptoms were noted.58 In the Inhaled
Steroids in Obstructive Lung Disease in Europe
(ISOLDE) study, treatment with fluticasone propio-
nate was shown to result in a 25% reduction in
exacerbations, a reduced need for oral corticoster-
oids, and a slower decline in health status,
compared with placebo.57 Furthermore, mean
post-treatment FEV1 was significantly higher in
fluticasone propionate-treated patients compared
with placebo-treated patients at endpoint.58
Therefore, despite the lack of effect on disease
progression in these trials (although a modest
effect on the rate of lung-function decline has
been shown in a recent meta-analysis of rando-
mised controlled trials),56 ICS therapy is recom-
mended for regular treatment in some patients
(those with frequent exacerbations),61,62 and
abrupt withdrawal has been associated with in-
creased likelihood of exacerbations.63
Oral corticosteroids (OCSs) have been associated
with a reduction in bone mineral density (BMD) and
an increased risk of osteoporosis and fractures.64,65
However, several studies in patients with COPD
have found that there is no significant increase in
fracture incidence due to ICS treatment compared
with placebo.57,60,66,67 The Lung Health Study II,
which looked at the safety and efficacy of inhaled
triamcinolone acetonide (600mcg bid) over 3
years, reported a 2% reduction in BMD in the
femoral neck with triamcinolone compared with
placebo, but the clinical relevance of this change isunclear.58 In addition, epidemiological investiga-
tions suggest that the excess risk observed with ICS
treatment in COPD is related to the underlying
disease rather than to this therapy, and as such, is a
factor that should be considered in all patients,
regardless of treatment.68
A number of retrospective studies have been
performed to assess the potential role of ICSs in
COPD mortality. A retrospective study in 22,620
elderly patients with COPD demonstrated that
during a 1-year follow-up period, ICS therapy was
associated with a relative risk reduction for all-
cause mortality of 29%, compared with those who
did not receive ICS therapy.69 A further cohort
analysis based on patients from the UK General
Practice Research database showed that use of ICSs
was associated with a significant reduction in death
compared with short-acting bronchodilators in COPD
patients (16%).70 However, it should be recognised
that there are limitations to such studies as they are
based on retrospective patient records. Therefore,
randomised controlled trials are needed to confirm
these reported effects.71 Very recently, Sin and
coworkers have shown that ICS can influence the
level of systemic inflammation112, highlighting a
potential beneficial effect of these drugs on another
important component of COPD.Combination therapies
LABA/ICS combination therapy
Given that LABAs and ICSs have complementary
mechanisms of action, targeting different arms of
the vicious cycle of COPD, a combination of the two
types of drug has the potential to address several
major components of COPD, including airflow
limitation, mucociliary dysfunction, and airway
inflammation. In the 52-week, double-blind TRial
of Inhaled STeroids ANd long-acting beta2 agonists
(TRISTAN) study, a combination of salmeterol and
fluticasone propionate was shown to result in
significantly greater improvements in FEV1 than
placebo, or either salmeterol or fluticasone pro-
pionate alone in patients with COPD.33 The number
of exacerbations per patient per year was reduced
by 25% with combination therapy, 20% with salme-
terol and 20% with fluticasone propionate com-
pared with placebo. In addition, combination
salmeterol/fluticasone propionate treatment pro-
duced a clinically significant improvement in
health-status questionnaire score, and the greatest
reductions in daily symptoms. The safety profile of
the combination treatment was comparable to
those of the individual agents.33 Two 24-week
studies have also investigated combined salmeterol
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250mcg and 50mcg/500mcg) and revealed signifi-
cant improvements in pre-dose FEV1, vs. salmeterol
alone or placebo, and in post-dose FEV1, vs.
fluticasone propionate alone or placebo. Greater
improvements in the Transition Dyspnoea Index
were seen versus placebo for the 50mcg/250mcg
dose, and versus placebo and individual treatments
alone for the 50mcg/500mcg dose.72,73
Likewise, two 12-month, double-blind studies in
adults with COPD have shown that a combination of
formoterol and budesonide can give clinically
meaningful benefits for patients with COPD.37,74
These studies have shown that therapy with
formoterol/budesonide reduces the need for re-
liever beta2-agonists, improves health-related
quality of life, reduces daily symptoms, and
significantly improves FEV1.
37,74 In addition both
studies found that combination therapy signifi-
cantly reduced the mean number of exacerbations
per patient per year, compared to placebo and
formoterol, but not budesonide alone.37,74
Importantly, an observational cohort study has
revealed that the combination of a LABA and an ICS
can offer increased survival; 3-year survival rates
were numerically higher in patients receiving
salmeterol and fluticasone propionate prescribed
concurrently, compared with those receiving either
agent alone.75 Furthermore, survival rates in all of
these patient groups were higher than those seen in
a reference group of patients who used bronchodi-
lators other than LABAs or ICSs.75 The results of this
observational cohort study require confirmation in
a randomized controlled setting. The ongoing 3-
year TORCH study comparing combination therapy
with salmeterol plus fluticasone propionate, with
each agent as monotherapy and placebo, is one
such trial which will evaluate all-cause mortality as
a primary efficacy endpoint.76 Over 6000 patients
have been randomised, and the results should help
answer many questions about long term effects of
LABAs and ICSs in patients with COPD.
Several mechanisms have been proposed to
explain the additive effects seen with the LABA/
ICS propionate combination, such as glucocorticoid-
mediated upregulation of beta2-receptor levels,
beta2-agonist induced nuclear translocation of
glucocorticoid receptors (GRs), and beta2-agonist
transcription factor modulation of the GR signalling
pathway.77 However, the mechanism by which this
combination therapy provides improved efficacy
needs further exploration. The positive effects of
LABAs on enhancing the anti-inflammatory effects
of ICSs may be particularly relevant in COPD
patients with a reduced anti-inflammatory respon-
se—so-called ‘steroid resistance’. It has beenhypothesised that steroid resistance is a result of
cigarette smoke-induced damage to the histone
deacetylase 2 (HDAC2) enzyme, which is involved in
GR-induced downregulation of proinflammatory
genes.51 However, a recent study in asthmatic
patients revealed that those patients who were
steroid-resistant also showed a failure in GR
translocation to the nucleus.78 Thus, if steroid
resistance is in fact due to a reduction in GR
translocation to the nucleus, the addition of a LABA
which increases nuclear localisation of the GR, may
overcome steroid resistance resulting in improved
anti-inflammatory effects. There is also the possi-
bility of combining LABAs, ICSs and long-acting
anticholinergics. This sort of combined therapy
could potentially target the major components of
the vicious cycle of COPD, and the therapeutic
benefits of the various combinations will need to be
studied in the future.Anticholinergic/beta2-agonist combinations
A combination of bronchodilatory agents with
different mechanisms of action can potentially
provide a greater clinical effect than administra-
tion of the single agents alone. In particular, the
combination of beta2-agonists and anticholinergic
agents provides the potential to target multiple
components underlying COPD, through their com-
plementary modes of action. Evidence for the
effectiveness of such combination treatments in
COPD can be seen in a 12-week, randomised,
parallel-group study in COPD patients treated with
the short-acting beta2-agonist, salbutamol, the
anticholinergic, ipratropium bromide, or a combi-
nation of both. This found that the combination
treatment was significantly superior to either agent
alone, in terms of peak FEV1, mean FEV1 (0–4 h),
and total area under the curve of the FEV1
response.79 Similar improvements in FEV1 response
were also seen when a combination of the LABA,
salmeterol, and ipratropium bromide was used.80
There are no data currently available on the role
and potential benefits derived from the combina-
tion of LABAs and the new long-acting antic-
holinergics (such as tiotropium) in COPD. Given
the superiority of tiotropium over ipratropium
bromide, a LABA/tiotropium combination is likely
to have improved efficacy over the results seen
with salmeterol and ipratropium bromide.Other available treatments
A number of other pharmacological therapies
are used in the treatment of COPD, including
antioxidants, antibiotics and vaccinations. Reactive
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inflammatory cells, or from cigarette smoke, are
believed to contribute to the pathophysiology of
COPD.81 Elevated levels of lipid peroxidation,
degraded proteins, and an increase in exhaled
nitric oxide and hydrogen peroxide, particularly
during exacerbations, all point to oxidative stress in
patients with COPD.82,83 Oxidative stress may
induce damage to lung tissue, increase mucus
production and have pro-inflammatory effects via
up-regulation of IL-8 and inducible NO synthase
(iNOS).84 The antioxidant N-acetylcysteine (NAC)
has been shown in clinical trials to improve
respiratory symptoms and reduce the rate and
duration of exacerbations in patients with
COPD.85,86 In animal models, NAC has also been
shown to inhibit thickening of the airway epithe-
lium and secretory cell hyperplasia induced by
cigarette smoke.87,88 The Bronchus trial is a multi-
center, randomised controlled study investigating
the potential therapeutic effect of NAC in patients
with COPD. Its preliminary results were reported at
the European Respiratory Society meeting held in
Vienna in September 2003. Despite an apparent
lack of effect of NAC upon the rate of decline of
FEV1, some potentially beneficial effects upon lung
hyperinflation were reported.
Elderly patients with COPD are particularly at
risk from influenza infections during colder months
of the year, and annual influenza vaccinations in
the winter and/or autumn are recommended in this
patient group.2 Pneumococcus vaccines may also
be of benefit to some COPD patients. Prophylactic
use of antibiotics is not recommended in COPD
patients but short-term antibiotic therapy plays an
important role in the treatment of COPD exacer-
bations.2,89
To date, there are no specific treatments avail-
able that target the pathophysiology of the
systemic component of COPD.17 Several non-phar-
macological therapies, such as domiciliary oxygen
therapy, pulmonary rehabilitation and nutritional
support, have shown positive effects, but there
remains a considerable unmet need for specific
therapies for the systemic component of COPD. It is
hoped that in the future, therapies will be
developed to address this need.Breaking the COPD vicious cycle—future
therapies
A number of new therapies are currently being
developed for COPD, including selective PDE4
inhibitors, protease inhibitors, retinoic acid, p38MAP kinase inhibitors, TNF-a inhibitors, new anti-
oxidants and CXCR2 antagonists. Many of these
therapies would be potentially combinable with
existing therapies that target airway inflammation
and/or mucociliary dysfunction in order to address
the multicomponent nature of COPD. In addition
TNF-a inhibitors and antioxidants may potentially
also address the systemic component of the vicious
cycle of COPD.Selective PDE4 inhibitors
Phosphodiesterase is a key enzyme in the cyclic
AMP (cAMP) signalling pathway. Because it is
present in inflammatory cells, PDE inhibitors may
also have anti-inflammatory properties. These may
be useful in the long-term treatment of COPD. A
major PDE type found in inflammatory cells is PDE4.
A number of preclinical studies have demonstrated
the anti-inflammatory properties of two selective
PDE4 inhibitors in development, cilomilast and
roflumilast. Cilomilast was shown to inhibit TNF-a
and IL-4 secretion in vivo in guinea pigs, and
roflumilast mediated responses against neutrophils,
eosinophils, monocytes, macrophages, dendritic
cells and T cells in vitro.90,91 Cilomilast treatment
appears to reduce the number of CD68+ and CD8+
cells in the bronchial biopsies of patients with
COPD.92 A preliminary randomised, dose-ranging
trial in patients with COPD demonstrated improved
lung function with cilomilast, compared with
placebo, after 6 weeks of therapy.93 In a further
study in COPD, roflumilast improved FEV1, forced
vital capacity (FVC), and peak expiratory flow rate
(PEFR) after 4 weeks to a greater degree than
placebo.94 Ongoing clinical trials will further assess
the therapeutic potential of these PDE4 inhibitors.Protease inhibitors
An imbalance between proteases and anti-pro-
teases in patients with COPD may lead to excess
protease activity in pulmonary tissues and tissue
damage.95 Neutrophil activation and migration into
the lungs is believed to be one of the major
features of the inflammatory component of COPD,
and represents a novel therapeutic target. Several
small molecule inhibitors of neutrophil elastase are
currently in clinical development, and have been
shown to protect against neutrophil elastase-
induced lung injury in experimental animals.96
Proteolytic enzymes other than neutrophil
elastase have been implicated in inflammation-
associated damage to lung tissue in COPD. The
therapeutic potential of inhibitors of cathepsin G
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phage-derived cathepsins B, L and S, is also being
investigated.97 Administration of endogenous anti-
proteases, such as secretory leukoprotease inhibi-
tor, a1-antitrypsin or tissue inhibitors of MMPs
(TIMPS), is another potential strategy for redressing
antiprotease deficiencies in the lung.
Retinoic acid
Emphysema, a key component of COPD, results
from progressive destruction of alveolar septae.
Retinoids are known to activate genes involved in
lung development and promote alveolar separation
and growth, and have, therefore, the potential to
address this structural component of COPD. A study
in a rat model of emphysema revealed that
administration of all-trans-retinoic acid (ATRA)
resulted in the reversal of the structural changes
associated with emphysema.98 A pilot study in 20
patients with severe emphysema did not provide
evidence of increased alveolarisation in the short
term, but it showed that ATRA was well-tolerated
and warrants further clinical investigation.99 In any
case, the realisation that there is potential for lung
regeneration opens a whole new area of investiga-
tion which may eventually lead to the ‘‘holy grail’’
of COPD treatment, this is, the restoration of a
normal lung structure and function. Eventually, the
use of pluripotent stem cells may contribute to this
goal.100
p38 mitogen activated protein kinase
inhibitors
Mitogen activated protein (MAP) kinases play a key
role in chronic inflammation, and one, p38 MAP
kinase, is involved in the expression of IL-8, TNF-a
and MMPs, the levels of which are increased in
COPD. Non-peptide p38 MAP kinase inhibitors have
been shown to have a wide range of anti-inflam-
matory activities in rats,101 although such a broad-
based activity may lead to some toxicity issues.102
Antioxidant therapy
The full potential of antioxidant therapy has yet to
be explored in COPD. The benefits of NAC in COPD
have not yet been fully clarified, as discussed
above. Newer, more potent antioxidants currently
in development, such as the spin-trap antioxidant
a-phenyl-N-tert-butyl nitrone, may prove to be
effective treatments for COPD. Spin-trap antiox-
idants form stable adducts with reactive oxygen
species, preventing them from oxidising lipids andproteins, therefore potentially protecting cells
from injury. The increased levels of oxidants in
the circulation of patients with COPD will inevitably
reduce their antioxidant capacity. Although there is
epidemiological evidence linking poor dietary in-
take of vitamins C and E with COPD, there have
been no controlled trials of these antioxidant
vitamins in the treatment of COPD.103 Oxidative
stress is thought to be one of the prime factors
contributing to the systemic components of COPD.
Therefore, newer antioxidant therapy may play a
significant role in targeting both the inflammatory
and systemic components of the vicious cycle of
COPD in the future.Tumour necrosis factor-a inhibitors
Another treatment with the potential to target
multiple components of COPD, is anti-TNF-a ther-
apy. TNF-a levels have been found to be elevated in
BAL and sputum samples of patients with
COPD.11,104 In addition to its pro-inflammatory
effects within the lungs, TNF-a may also be
implicated in the systemic component of COPD.
Increased production of TNF-a by cells in the
inflamed lung may contribute to priming of circu-
lating inflammatory cells; indeed, studies have
shown that patients with COPD have increased
levels of circulating soluble TNF-a in the peripheral
circulation.105,106 This increase in circulating TNF-a
may be responsible for the severe muscle wasting
seen in patients with COPD, due to TNF-a-induced
skeletal muscle apoptosis.107 As such, anti-inflam-
matory drugs targeted against TNF-a such as
humanised anti-TNF-a antibodies, or recombinant,
soluble TNF-a receptor may be suitable treatments
for COPD.CXCR2 antagonists
Recruitment and activation of inflammatory cells in
the lung significantly contributes to the pathophy-
siology of COPD. Its control may therefore be an
attractive strategy for therapeutic interventions.
The concentration of IL-8 is increased in the
bronchoalveolar lavage of COPD patients.108 IL-8
activates neutrophils via a low affinity G-protein
coupled receptor (CXCR1), and a high affinity
receptor (CXCR2). It has been shown that inhibition
of CXCR2 is sufficient to abolish IL-8 induced
chemotaxis of human neutrophils,109 and lipopoly-
saccharide-induced lung neutrophil infiltration in
rabbits.110 Small molecule antagonists of the IL-8
receptors (e.g., SB225002, SB265610) have now
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patients with COPD.
Angiotensin converting enzyme (ACE)
inhibitors
As our understanding of the pathophysiology of COPD
deepens, we may find that pharmacological agents
originally developed for other indications have
beneficial effects on COPD. One example of this
may be the use of angiotensin converting enzyme
(ACE)- inhibitors for the treatment of muscle wasting
in patients with COPD. To date, there is no data to
support this potential indication, but the efficacy of
ACE inhibitors to this end has been demonstrated in
patients with chronic heart failure, who also develop
skeletal muscle dysfunction.111Concusion and summary
Chronic obstructive pulmonary disease is a multi-
component disease, comprising a number of pro-
cesses that interact with each other in a ‘COPD
vicious cycle’. To treat the disease adequately,
therapeutic intervention should aim to break this
cycle. To date, only smoking cessation has been
shown to unequivocally affect the decline in FEV1.
Monotherapy with short-acting bronchodilators tar-
gets elements of airflow limitation, but may not
address other components of the disease. LABAs can
affect mucociliary transport and reduce bacterial
damage, and may also have positive effects on the
inflammatory component of the vicious cycle of
COPD. Anticholinergics may reduce mucus hyperse-
cretion. ICSs target the airway inflammation and
structural changes components of the vicious cycle
by reducing the release of inflammatory mediators
and the numbers of inflammatory cells in the lungs.
Combination therapy offers the potential to target
several of these components at once, and there is
also evidence that combining LABAs and ICSs has
improved efficacy over treatment with the indivi-
dual agents alone. Future combination strategies
may prove to be even more effective in the
treatment of COPD. Compounds currently in devel-
opment, such as newer antioxidants and type 4 PDE
inhibitors, may also provide more effective treat-
ments in the future due to their potential multiple
modes of action. Finally, the extrapulmonary,
systemic component of COPD has yet to be properly
addressed in terms of possible pharmacologic inter-
vention. More research is required to tackle this
important, but poorly understood component of the
vicious cycle of COPD.Acknowledgment
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